TPA pharmaceutical gel testing — and TPA of creams, ointments, hydrogels, soft capsules, and even tablets — is a two-cycle compression test that extracts seven quantitative parameters from a single measurement: hardness, fracturability, cohesiveness, springiness, gumminess, chewiness, and resilience. Developed at MIT by Szczesniak and refined by Bourne in the 1970s, Texture Profile Analysis became the pharmaceutical industry's standard multi-parameter method for characterizing semi-solid and viscoelastic dosage forms. This guide walks through TPA theory, the seven parameters, a validated setup protocol on the KHT TA-30, curve interpretation, and how to build GMP-defensible specification limits for batch release.
A correctly configured TPA takes less than 90 seconds per sample, produces reproducibility under 5% CV on well-formulated gels, and generates a comprehensive mechanical fingerprint that single-compression methods cannot match. For pharmaceutical R&D, TPA accelerates formulation screening. For QC, TPA provides multi-dimensional release criteria that catch out-of-specification batches invisible to single-parameter tests.
What Is TPA and Why It Matters for Pharmaceutical Formulations
Texture Profile Analysis simulates the action of repeated compression — originally the first and second bite in sensory evaluation, but in pharmaceutical context the repeated mechanical stress a gel experiences during tube extrusion, a tablet during handling, or a capsule during packaging and transport. The test compresses a sample to a defined strain (typically 40–60% deformation), waits a defined hold period, releases, waits a defined recovery period, then compresses again to the same strain.
The resulting force-time curve contains two peaks and the geometry of the recovery. From these, seven derived parameters quantify the sample's mechanical behavior:
- Hardness — peak force during the first compression cycle (N)
- Fracturability — force at first significant fracture during the first compression, if present (N)
- Cohesiveness — ratio of work done during second compression to work done during first compression (dimensionless, 0–1)
- Springiness — ratio of recovered height between first and second compression to the original compression distance (dimensionless, 0–1)
- Gumminess — hardness × cohesiveness (N; applies to semi-solid samples)
- Chewiness — gumminess × springiness (N; applies to solid/semi-solid samples)
- Resilience — ratio of the withdrawal work to the compression work during the first compression cycle (dimensionless, 0–1)
Why TPA matters in pharma: a single-compression test gives you one number — typically peak force or mean force. TPA gives seven correlated numbers that together characterize the sample's elasticity, plasticity, recovery behavior, and internal cohesion. For a topical hydrocortisone cream, hardness alone cannot distinguish a well-formulated cream from one that is over-thickened; cohesiveness and springiness do. For a soft capsule shell, hardness alone cannot catch brittleness developing during stability storage; fracturability and resilience do.
TPA is widely used for: pharmaceutical gels (hydrogels, carbopol gels, cellulose gels, alginate rafts), creams (O/W and W/O emulsions), ointments, hydrocortisone and other semi-solid topicals, soft gelatin capsules (though puncture testing is often preferred), suppositories, alginate raft-forming formulations (per British Pharmacopoeia), and occasionally tablets for comparing coating elasticity. USP <1724> "Semisolid Drug Products — Performance Tests" explicitly references rheological and mechanical characterization; TPA is a standard method cited in multiple pharmaceutical texture review papers.
The 7 TPA Parameters: Definitions and Pharmaceutical Significance
1. Hardness (N) — the peak force recorded during the first compression cycle. For pharmaceutical gels, typical hardness ranges from 0.1N (thin hydrogels) to 15N (firm ointments). For tablets, hardness ranges 50–300N. Higher hardness generally correlates with greater internal structure and higher bioadhesion strength. A hardness drop over stability storage is a classic early-warning indicator of formulation degradation.
2. Fracturability (N) — the force at the first significant break in the force-time curve during the first compression. Many pharmaceutical gels do not fracture during TPA compression and this parameter is recorded as "none" or null. For gels that do fracture (carbopol at high concentration, certain wax-based ointments), fracturability captures the brittle-to-plastic transition. In soft-capsule shell TPA, fracturability is the shell rupture force.
3. Cohesiveness (dimensionless, 0–1) — the ratio of the area under the second compression curve (A2) to the area under the first compression curve (A1). Cohesiveness = A2/A1. Values near 1.0 indicate highly cohesive samples that recover most of their internal structure between compressions (well-formulated hydrogels, alginate rafts); values near 0.2–0.5 indicate samples that yield structure irreversibly (creams and ointments where the first compression destroys internal organization). Cohesiveness is one of the most discriminating TPA parameters for pharmaceutical formulation screening.
4. Springiness (dimensionless, 0–1) — the ratio of the distance the sample recovers between the two compression cycles (measured at the time the force reaches the detection threshold on the second compression) to the compression distance on the first cycle. Higher springiness indicates more elastic behavior. Pharmaceutical gels typically range 0.3–0.9; ointments 0.2–0.5; creams 0.3–0.6. Springiness is sensitive to changes in crosslink density, polymer molecular weight, and storage-induced syneresis.
5. Gumminess (N) — calculated as hardness × cohesiveness. Applies to semi-solid samples (gels, creams, ointments). Gumminess captures the resistance to disintegration during mastication or, in pharma context, during extrusion and spreading. Typical pharma hydrogel gumminess: 0.5–8 N.
6. Chewiness (N) — calculated as gumminess × springiness = hardness × cohesiveness × springiness. Combines all three primary TPA parameters into a single composite. Chewiness is most often reported for solid dosage forms (gummies, chewable tablets, medical confectionery) rather than topical gels.
7. Resilience (dimensionless, 0–1) — the ratio of the work done by the sample during the first-compression withdrawal (elastic recovery) to the work done during the first-compression descent (compression). Calculated from the withdrawal portion of the first compression curve only. Resilience is a fast-response elastic parameter; it detects early-stage structural recovery before the longer-timescale springiness measurement. Sensitive to crosslink density changes and useful for stability-indicating QC.
Setting Up a TPA Test on the KHT TA-30 (Speed, Distance, Trigger, Delay)
A reproducible pharmaceutical TPA requires six parameters to be locked down. Below is the standard protocol for pharmaceutical gels, creams, and ointments on the KHT TA-30; adjust only with formulation-specific justification and record changes in the audit trail.
Step-by-Step TPA Protocol for Pharmaceutical Gels
Step 1. Select the probe. For pharmaceutical semi-solid TPA, the standard probe is a 35 mm or 40 mm flat cylindrical probe (P/35 or P/40 in SMS nomenclature; equivalent KHT-branded probes ship with the KHT TA-30 pharma starter set). For small-sample or high-throughput work, a 25 mm probe is acceptable provided it is held constant across the study. For very firm ointments or wax-based topicals, use a 20 mm probe to avoid exceeding load cell capacity.
Step 2. Prepare the sample. Transfer the gel, cream, or ointment into a standard 60 mm diameter × 25 mm deep sample cup, filling to within 2 mm of the rim. Avoid air bubbles — tap the cup gently to release entrapped air before testing. Equilibrate to 25.0 °C ± 0.5 °C (or 32.0 °C for skin-temperature simulation tests). A Peltier-controlled sample stage is recommended for regulated methods.
Step 3. Configure test parameters. On the KHT TA-30 software, select TPA from the method library and set:
| Parameter | Value | Notes |
|---|---|---|
| Pre-test speed | 1.0 mm/s | Probe approach before contact |
| Test speed | 2.0 mm/s | Compression and withdrawal speed |
| Post-test speed | 2.0 mm/s | Return speed after cycle |
| Trigger force | 0.05 N | Contact detection threshold |
| Compression strain | 50% | Deformation as % of sample depth |
| Hold time at max strain | 5.0 s | Dwell between compression and withdrawal |
| Delay between compressions | 5.0 s | Time between first and second cycles |
| Data acquisition rate | 400 Hz | Standard for semi-solid TPA |
Step 4. Lower the probe to the sample surface. Use the software jog-down until the probe is within 5 mm of the gel surface. Engage auto-positioning; the instrument will descend at pre-test speed and detect the 0.05 N trigger.
Step 5. Run the test. The instrument executes: compression at 2 mm/s to 50% strain → 5 s hold → withdrawal at 2 mm/s to the trigger position → 5 s delay → compression at 2 mm/s to 50% strain → 5 s hold → withdrawal to start position. Total test duration approximately 45–60 seconds depending on sample depth.
Step 6. Review the curve. Verify two clean compression peaks, clean separation between cycles, and no probe-adhesion artifact during withdrawal (if adhesion is present, consider a silicone probe release coating). Reject any curve where the trigger fires on air, where fracture occurs during the hold phase, or where the sample overflows the cup.
Step 7. Extract parameters. The KHT TA-30 Pharma Software auto-calculates all seven TPA parameters from each curve, with operator review and approval before the result is released to the audit trail. Export results as CSV for LIMS intake or as PDF for batch records.
Step 8. Repeat for statistical validity. Run n = 6 replicates minimum per batch. Discard outliers using Grubbs' test at p = 0.05; retain the remaining replicates for statistical reporting. Record mean, SD, and CV% for each of the seven parameters.
Acceptance Criteria Setup — Typical Ranges for Pharmaceutical Gels
Below are representative TPA acceptance bands for common pharmaceutical semi-solid formulations. These are starting points; finalize via formulation-specific validation with at least three batches.
| Parameter | Hydrocortisone Cream | Carbopol Hydrogel | Ophthalmic Gel | Vaginal Suppository |
|---|---|---|---|---|
| Hardness (N) | 2.0–5.0 | 0.8–2.5 | 0.3–1.2 | 8–18 |
| Cohesiveness | 0.35–0.55 | 0.60–0.85 | 0.55–0.80 | 0.30–0.50 |
| Springiness | 0.40–0.65 | 0.70–0.90 | 0.65–0.85 | 0.35–0.55 |
| Gumminess (N) | 0.7–2.5 | 0.5–2.0 | 0.2–0.9 | 2.8–9.0 |
| Resilience | 0.15–0.35 | 0.25–0.50 | 0.30–0.55 | 0.10–0.25 |
Interpreting TPA Curves for Gels, Creams, Tablets and Capsules
TPA interpretation is pattern recognition, not single-number comparison. Train QC analysts to read the shape of the curve, not just the derived parameters.
Healthy pharmaceutical gel curve: clean first-compression peak with smooth rise to Hardness; brief plateau during the 5 s hold; clean withdrawal with modest adhesion tail; full recovery of probe to trigger position; second compression peak at 60–85% of the first peak magnitude; smooth withdrawal. Cohesiveness in the 0.6–0.85 band, springiness in the 0.7–0.9 band. This is a well-crosslinked, elastically recovering gel.
Over-sheared or degraded cream: first compression is normal, but second compression peak is less than 30% of the first. Cohesiveness below 0.3. The emulsion has yielded irreversibly under the first compression — structure does not recover in the 5 s delay. Common failure mode during stability storage, mechanical shear during manufacturing, or freeze-thaw cycling.
Brittle failure in soft capsule TPA: sharp fracture event during the first-compression rise, with force dropping to near-zero before the 50% strain target is reached. Fracturability captured as the pre-fracture peak force. Softgel shells that become brittle during storage show this pattern; cohesiveness becomes meaningless because there is no structural continuity between cycles.
Adhesion-dominated ointment: first-compression hardness is normal, but a large negative (adhesive) area appears during withdrawal. High gumminess and low springiness. Typical of petrolatum-based ointments and bioadhesive hydrogels where mucosal residence is a design objective. Adhesive work (Wadh) is often reported alongside TPA for these formulations.
Tablet TPA (less common): tablets rarely undergo true TPA because the first compression permanently damages the tablet. However, for elastic or modified-release coated tablets, a modified TPA with very low strain (5–15%) and increased post-hold delay can characterize coating elasticity and core compression rebound. This is a specialized method — consult formulation scientists before implementing.
Red flags on the curve:
- Double peaks on the first compression → probe misalignment or sample heterogeneity
- Non-zero force during the delay period → sample extrusion around probe edge; increase probe-to-cup clearance
- Second compression force exceeds first → sample settled during hold or temperature drift; re-equilibrate
- Ragged/noisy curve → trigger too low; raise to 0.1 N or check load cell zeroing
GMP Documentation: Setting Specification Limits and Batch Release Criteria
TPA data is only as useful as the regulatory documentation surrounding it. For GMP batch release, treat TPA like any other mechanical release test: document the method, validate the instrument, lock the SOP, and set specification bands with formal DOE.
Method validation. TPA method validation for pharmaceutical use should address: specificity (does the method distinguish between intended formulation variants?), accuracy (reference standard TPA on certified gel materials), precision (intra-day and inter-day CV% across operators), linearity (if the method will be used across a concentration range), robustness (small changes in speed, strain, and temperature do not invalidate results). Typical acceptance: CV% below 8% for hardness, below 12% for cohesiveness and springiness, below 15% for resilience.
Specification band development. Build TPA specification bands from at least three validation batches of known-good formulation, supplemented by stress batches (deliberately under-mixed, over-mixed, stored at accelerated conditions). Set initial acceptance bands at mean ± 3 SD from the pooled validated batch data, then narrow based on stability study outcomes. Do not set specification bands tighter than the instrument's demonstrated method precision — this generates false out-of-specification events.
21 CFR Part 11 documentation. Every TPA run recorded for GMP purposes must include: timestamp (NIST-traceable), operator identity with electronic signature, method ID with version number, sample ID traceable to batch record, raw curve (not just derived parameters), operator review annotation, and reviewer approval signature with timestamp. The KHT TA-30 pharma software enforces all of these as standard; verify the audit trail cannot be modified or deleted even by administrator accounts.
Batch release decision tree. A typical pharmaceutical gel batch release from TPA: pass all seven parameters within acceptance bands → release. One parameter fails → escalate to QA for investigation (typical cause: single outlier; re-run n = 6 replicates). Two or more parameters fail → OOS investigation, CAPA, batch hold pending root-cause analysis. Never release a batch on a single parameter pass if others are borderline.
Stability study integration. Run TPA at every pull point (typically 0, 3, 6, 9, 12, 18, 24, 36 months for a 3-year stability protocol) on stored samples. Plot hardness, cohesiveness, and springiness over time. Trending these three parameters catches most physical stability failures earlier than single-parameter viscosity testing.